Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer

NCT00427999 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: imatinib mesylate
DRUG: Treosulfane
DRUG: etoricoxib
DRUG: pioglitazone
DRUG: dexamethasone

Sponsor

Novartis Pharmaceuticals